全体基調講演

2019年8月6日(火) | 4:15 - 5:30 pm

パネルディスカッション:次世代免疫療法

CHI’s Immuno-Oncology Summit brings you the latest advances in immunotherapy every year. This panel of industry thought leaders will discuss the technology advances and implementation strategies for next-generation immunotherapies, including emerging immunotherapy combinations, bispecific antibodies, oncolytic virotherapy, adoptive cell therapy, personalized vaccines and neoantigen targeted therapies, small molecules and ADCs, cytokines, and innate immunity targeted therapies.

Moderator

Pamela Carroll, PhD

Senior Vice President, Immuno-Oncology, Genocea Biosciences

 

 

 

 

Panelists

Rakesh Dixit

PhD, DABT, President & CEO, Bionavigen

 

 

 

 

Tara Arvedson, PhD

Director, Oncology Research, Amgen

 

 

 

 

Stephen Doberstein, PhD

Chief Research and Development Officer, Nektar Therapeutics

 

 

 

 

Raymond Tesi, MD

CEO/CMO, INmune Bio

 

 

 

 

David Kirn, MD

Co-Founder & Executive Chairman, IGNITE Immunotherapy

 

 

 

 

2019年8月8日(木) | 8:25 - 9:30 am

パネルディスカッション:がん免疫療法の分野における提携とライセンス供与

Big pharma and biotech are under pressure to compete in the booming Immuno-Oncology market and to capitalize on new technologies and innovations to bring next-generation immunotherapies to the patients. This insider panel will share what they look for in a partner or investment, and discuss opportunities for collaboration or in-licensing of novel immunotherapies, IO targets or biomarkers, and potential combination therapies.

Moderator

Griffith_MelindaMelinda Griffith, JD

Chief Legal Counsel and Vice President, Strategic Alliances

 

 

 

 

Panelists

Michael Woo, MBA

Head, Search & Evaluation, Immuno-Oncology, Business Development & Licensing, Novartis Institutes for BioMedical Research, Inc.

 

 

 

 

Kathryn McCabe, PhD

Senior Director, Business Development, Emerging Technology and Innovation, Eli Lilly and Company

 

 

 

 

Scott M. DeWire, PhD

Global Head, Business Development and Licensing, Cancer Immunology, Boehringer Ingelheim Pharmaceuticals, Inc.

 

 

 

 

Philip Arlen, MD

President & CEO, Precision Biologics

 

 

 

 

Stephen Doberstein, PhD

Senior Vice President, R&D and Chief Research and Development Officer, Nektar Therapeutics

* 不測の事態により、事前の予告なしにプログラムが変更される場合があります。

Choose your language
Traditional Chinese
Simplified Chinese
Korean
English


更新履歴
2019/07/23
講演者・スポンサー更新
2019/07/09
スポンサー更新
2019/06/20
スポンサー更新
2019/05/17
アジェンダ・スポンサー更新
2019/04/10
アジェンダ更新
2019/04/09
アジェンダ・スポンサー更新
2019/03/28
スポンサー更新




メール配信サービス